ABL Bio Corp.

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis

Signs of broader recovery are emerging in the South Korean biotech sector following the landmark US approval of Yuhan Corporation 's novel lung cancer drug Lazcluze (lazertinib) in August through lic

Biopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome